News
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...
TipRanks on MSN6h
AbbVie’s Atogepant Study: A New Hope for Menstrual Migraine Relief
Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3 clinical study ...
TipRanks on MSN6h
AbbVie’s Bimatoprost SR Study: A New Horizon in Glaucoma Treatment
Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie has recently completed a Phase 3b clinical ...
AbbVie has performed better than the market over the past decade. The company has lost a major product, but its lineup and ...
AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...
Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...
The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.
Pharmaceutical Technology on MSN7d
AbbVie expands North Chicago API production with $195m investment
AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...
AbbVie has announced a USD 195 million investment in its North Chicago, Illinois manufacturing plant to expand domestic ...
The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...
AbbVie (NYSE:ABBV) invests $195M in North Chicago for API production, boosting U.S. pharmaceutical manufacturing. Read more ...
AbbVie, a global leader in life sciences, announced Tuesday the company’s is investing $195 million to expand its North ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback